Putting SARS-CoV-2 where it belongs: Identification of potential therapeutic targets with single cell analysis
November 11 @ 9:00 am - 10:00 am PST
In this webinar, we discuss efforts to develop a lung organoid model using human pluripotent stem cells (hPSC-LOs) to inform our understanding of SARS-CoV-2 infection and the immune response in both a physiologically relevant context and in specific lung cell types. We also generated complementary hPSC-derived colonic organoids (hPSC-COs) to explore the response of colonic cells to SARS-CoV-2 infection. Using hPSC-LOs, we performed a high throughput screen of FDA-approved drugs and identified entry inhibitors of SARS-CoV-2, including imatinib, mycophenolic acid (MPA), and quinacrine dihydrochloride (QNHC). Treatment at physiologically relevant levels of these drugs significantly inhibited SARS-CoV-2 infection of both hPSC-LOs and hPSC-COs.